Marksans Pharma gets final nod for Cetirizine Hydrochloride Tablets from USFDA

11 Jan 2022 , 03:13 PM

Shares of Marksans Pharma Limited have surged by 4.06% soon after it announced the approval of its drugs. The shares are currently trading at Rs 64.10 from a previous closing price of Rs 61.60.

Marksans Pharma Limited has announced that it has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg.

These drugs are indicated for the treatment of perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose.

The products will be marketed under store brand labels and is comparable to the brand Zyrtec®.